FDA User Fee Bill Would Require Diversity Action Plans for Clinical Trials

J.W. Schomisch
May 6, 2022 at 02:53 PM EST
Legislation to reauthorize the FDA’s user fee programs would "ensure clinical trials are representative of diverse populations," according to the leadership of the House Energy and Commerce Committee, which released a draft of the legislation May 4. The Senate version of the bill contains none of the trial provisions. The bill – H.R. 7667 - Food and Drug Amendments of 2022, i... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Related Articles